zintick

Intellia Therapeutics NTLA

Intellia Therapeutics, Inc. · Nasdaq · In Vitro & In Vivo Diagnostic Substances

$13.23-0.68%close on Oct. 29, 2026 · volume 4.7M · Yahoo Finance

Price, last 48 sessions

$12.00$13.00Sept. 2026Oct. 2026
Aug. 24, 2026 to Oct. 29, 2026 · high $13.51 · low $11.16 · SEC filing, placed when SEC released it

Our coverage

Nothing published yet.

Insider buying and selling

DateInsiderTradeSharesAvg. priceValue
Oct. 2, 2026Michael P. Dube
VP, Chief Accounting Officer
Sold1,864$12.43$23,170
Aug. 21, 2026John M. Leonard
President and CEO, director
Sold
10b5-1 plan
2,785$13.00$36,205
Aug. 20, 2026John M. Leonard
President and CEO, director
Sold
10b5-1 plan
19,890$12.60$250,614
July 22, 2026Edward J. Dulac III
EVP, Chief Financial Officer
Sold8,111$11.25$91,249

Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.

Recent SEC filings

All 9 →
  • 4Oct. 28, 2026, 4:06 p.m. ETView on SEC.gov
  • 4Oct. 6, 2026, 4:05 p.m. ETView on SEC.gov
  • 8-KSept. 8, 2026, 4:05 p.m. ETView on SEC.gov

    Regulation FD disclosure · Other events · Financial statements and exhibits

  • 8-KSept. 4, 2026, 4:06 p.m. ETView on SEC.gov

    Entry into a material definitive agreement · Creation of a direct financial obligation · Regulation FD disclosure · Financial statements and exhibits

  • 4Aug. 24, 2026, 4:05 p.m. ETView on SEC.gov
  • SCHEDULE 13GAug. 7, 2026, 9:54 a.m. ETView on SEC.gov
  • 10-QAug. 6, 2026, 4:05 p.m. ETView on SEC.gov
  • 8-KAug. 6, 2026, 7:45 a.m. ETView on SEC.gov

    Results of operations and financial condition · Financial statements and exhibits